EA200970425A1 - Способы лечения расстройств, выражающихся в разрушительном поведении - Google Patents

Способы лечения расстройств, выражающихся в разрушительном поведении

Info

Publication number
EA200970425A1
EA200970425A1 EA200970425A EA200970425A EA200970425A1 EA 200970425 A1 EA200970425 A1 EA 200970425A1 EA 200970425 A EA200970425 A EA 200970425A EA 200970425 A EA200970425 A EA 200970425A EA 200970425 A1 EA200970425 A1 EA 200970425A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treating disorders
destructive behavior
methods
disorder
causing
Prior art date
Application number
EA200970425A
Other languages
English (en)
Other versions
EA015690B1 (ru
Inventor
Магали Хаас
Original Assignee
Янссен Фармацевтика, Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика, Н.В. filed Critical Янссен Фармацевтика, Н.В.
Publication of EA200970425A1 publication Critical patent/EA200970425A1/ru
Publication of EA015690B1 publication Critical patent/EA015690B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение касается способа лечения расстройств, выражающихся в разрушительном поведении, в том числе кондуктивного расстройства и вызывающего оппозиционного расстройства, включающего введение нуждающемуся в этом субъекту терапевтически эффективного количества одного или более карбаматных соединений формулы 1 и/или формулы 2, которые определены и показаны ниже. Настоящее изобретение касается способа лечения расстройств, выражающихся в разрушительном поведении, в том числе кондуктивного расстройства и вызывающего оппозиционного расстройства, который включает монотерапию и в альтернативном варианте совместную терапию с применением по меньшей мере одного дополнительного психотропного лекарственного средства.
EA200970425A 2006-10-27 2007-10-11 Способы лечения расстройств, выражающихся в разрушительном поведении EA015690B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86313706P 2006-10-27 2006-10-27
PCT/US2007/081048 WO2008070277A2 (en) 2006-10-27 2007-10-11 Methods for treating disruptive behavior disorders

Publications (2)

Publication Number Publication Date
EA200970425A1 true EA200970425A1 (ru) 2009-12-30
EA015690B1 EA015690B1 (ru) 2011-10-31

Family

ID=39469514

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970425A EA015690B1 (ru) 2006-10-27 2007-10-11 Способы лечения расстройств, выражающихся в разрушительном поведении

Country Status (19)

Country Link
US (1) US20080103127A1 (ru)
EP (1) EP2089015B1 (ru)
JP (1) JP2010508279A (ru)
KR (1) KR20090088379A (ru)
CN (1) CN101646432A (ru)
AT (1) ATE489083T1 (ru)
AU (1) AU2007329779A1 (ru)
BR (1) BRPI0718318A2 (ru)
CA (1) CA2667510A1 (ru)
CO (1) CO6160292A2 (ru)
DE (1) DE602007010818D1 (ru)
EA (1) EA015690B1 (ru)
ES (1) ES2354319T3 (ru)
IL (1) IL198396A0 (ru)
MX (1) MX2009004552A (ru)
NO (1) NO20091659L (ru)
SV (1) SV2009003241A (ru)
WO (1) WO2008070277A2 (ru)
ZA (1) ZA200903652B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
WO2001013904A2 (en) * 1999-08-20 2001-03-01 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
RS50505B (sr) * 2001-02-27 2010-03-02 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju anksioznih poremećaja

Also Published As

Publication number Publication date
EP2089015A2 (en) 2009-08-19
CN101646432A (zh) 2010-02-10
ZA200903652B (en) 2010-08-25
ATE489083T1 (de) 2010-12-15
DE602007010818D1 (de) 2011-01-05
EA015690B1 (ru) 2011-10-31
MX2009004552A (es) 2009-11-10
CO6160292A2 (es) 2010-05-20
WO2008070277A2 (en) 2008-06-12
SV2009003241A (es) 2010-04-15
CA2667510A1 (en) 2008-06-12
AU2007329779A1 (en) 2008-06-12
ES2354319T3 (es) 2011-03-14
IL198396A0 (en) 2010-02-17
US20080103127A1 (en) 2008-05-01
EP2089015B1 (en) 2010-11-24
KR20090088379A (ko) 2009-08-19
WO2008070277A3 (en) 2008-08-07
JP2010508279A (ja) 2010-03-18
NO20091659L (no) 2009-05-26
BRPI0718318A2 (pt) 2013-11-26

Similar Documents

Publication Publication Date Title
EA200870556A1 (ru) Комбинированная терапия в лечении эпилепсии и родственных расстройств
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201070619A1 (ru) Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
EA201290919A1 (ru) Индазольные соединения и их применение
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
EA200870470A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
WO2007137164A3 (en) Co-therapy for the treatment of epilepsy and related disorders
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201200406A1 (ru) Соединения и композиции, которые являются модуляторами активности tlr
ATE534378T1 (de) Titrierung von tapentadol
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20082473L (no) Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
NO20084368L (no) Stabile emulsjonsformuleringer
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009004798A (es) Tratamiento de los trastornos generalizados del desarrollo.
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения
PE20081751A1 (es) Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU